MedTrace Logo

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

NCT06379646 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-08-29

No results posted yet for this study

Summary

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease

Conditions

Interventions

OTHER

YTS109

Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • China Immunotech (Beijing) Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huji Xu, MD,Ph.D · Shanghai Changzheng Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2025-04-21
Completion
2026-04-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06379646 on ClinicalTrials.gov